Immunotherapies with immune checkpoint inhibitors (ICIs), such as antibodies against the programmed cell death protein-1 (anti-PD-1) or its ligand PD-L1, have changed the therapeutic landscape of cancer. This evidence concerns the gene PDCD1 and cancer.